Village Global Podcast Health Stories: Early Cancer Screening with Gabriel Otte
Oct 31, 2018
34:14
Gabriel Otte (@gabeotte), CEO and co-founder of Freenome, joins Erik on this episode of Venture Stories to talk about cancer screening.
Gabriel starts out by talking about why he got into the cancer screening space and how Freenome got started.
He lays out the different methods of cancer detection and why Freenome has chosen their specific approach to the problem. Erik asks how it compares to other companies working on similar problems and Gabriel helps create a market map of the space.
Gabriel points out that 93 million people in the United States were instructed by their doctor to be screened for colorectal cancer last year but 70 million of them did nothing at all. He talks about why Freenome has chosen to hone in on this specific type of cancer screening and why it lends itself to an improved UX.
They move on to a discussion of the uniqueness of building a product and company in the health space and why the dynamics are so different than those of other tech companies. Gabriel talks about the FDA approval process and why it pays to engage with them early, as well as how a company should go about ensuring that their tests will be reimbursed by payers.
Thanks for listening — if you like what you hear, please review us on your favorite podcast platform.
Gabriel starts out by talking about why he got into the cancer screening space and how Freenome got started.
He lays out the different methods of cancer detection and why Freenome has chosen their specific approach to the problem. Erik asks how it compares to other companies working on similar problems and Gabriel helps create a market map of the space.
Gabriel points out that 93 million people in the United States were instructed by their doctor to be screened for colorectal cancer last year but 70 million of them did nothing at all. He talks about why Freenome has chosen to hone in on this specific type of cancer screening and why it lends itself to an improved UX.
They move on to a discussion of the uniqueness of building a product and company in the health space and why the dynamics are so different than those of other tech companies. Gabriel talks about the FDA approval process and why it pays to engage with them early, as well as how a company should go about ensuring that their tests will be reimbursed by payers.
Thanks for listening — if you like what you hear, please review us on your favorite podcast platform.